Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.30 |
| ▸ | PDE6C | P51160 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3850195 | 0.96 | PPARA (0.37) | PPARAMAPK14ALDH1A1NPSR1MEN1 | |
| SCHEMBL4916708 | 0.93 | PPARA (0.38) | PPARAMAPK14ALDH1A1NPSR1MEN1 | |
| SCHEMBL3881591 | 0.93 | PPARA (0.41) | PPARAMAPK14ALDH1A1NPSR1MEN1 | |
| SCHEMBL3841929 | 0.91 | PPARA (0.36) | PPARAMAPK14ADORA2APKM | |
| SCHEMBL3842114 | 0.89 | PPARA (0.34) | PPARAMAPK14ALDH1A1NPSR1MEN1 | |
| SCHEMBL4912505 | 0.89 | PPARA (0.37) | PPARAMAPK14ALDH1A1NPSR1MEN1 | |
| SCHEMBL3847182 | 0.87 | MAPK14 (0.35) | PPARAMAPK14NPSR1ADORA2ARECQL | |
| SCHEMBL3844603 | 0.87 | PDE5A (0.34) | ALDH1A1NPSR1MEN1POLBKMT2A | |
| SCHEMBL4922143 | 0.85 | PPARA (0.37) | PPARAMAPK14ADORA2ARECQLPKM | |
| SCHEMBL4921723 | 0.85 | PKM (0.34) | PPARAMAPK14ALDH1A1ADORA2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1793828-A4 | FIBRATE COMPOUNDS HAVING PPAR AGONIST ACTIVITY | REDDYS LAB LTD DR (IN) | 2009-09-02 | — | — | EP | disclosed |
| US-20080114005-A1 | 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-05-15 | — | — | US | disclosed |
| US-20080114005-A1 | 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-05-15 | — | — | US | disclosed |
| US-20080114005-A1 | 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-05-15 | — | — | US | disclosed |
| EP-1793828-A2 | FIBRATE COMPOUNDS HAVING PPAR AGONIST ACTIVITY | Dr. Reddy's Laboratories Ltd. (IN) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006029075-A2 | FIBRATE COMPOUNDS HAVING PPAR AGONIST ACTIVITY | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114005-A1 | 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity | PPARA, PPARD, PPARG | PPARA 1/4885MAPK14 3697/4885ALDH1A1 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.